Showing 683 results
-
Media Release /Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis¹…
-
Media Release /Approximately 3 million people in the US suffer from HFpEF, a life-threatening condition associated with frequent heart failure hospitalizations and emergency room visits, for which no treatment…
-
Media Release /
-
Media Release /FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
-
Media Release /FDA granted an indication for active Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD, a serious and rare inflammatory disorder with high unmet medical need1,2…
-
Media Release /Novartis donates 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency Donation builds on Novartis efforts in the US for communities impacted by…
-
Media Release /Novartis worked with U.S. Food and Drug Administration (FDA) to update BEOVU (brolucizumab-dbll) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1…
-
Media Release /
-
Media Release /More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years(1) Study conclusions are drawn from the largest dataset and…
-
Media Release /
